GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chimerix Inc (STU:CXF) » Definitions » EV-to-EBIT

Chimerix (STU:CXF) EV-to-EBIT : 0.79 (As of May. 26, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Chimerix EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Chimerix's Enterprise Value is €-68.39 Mil. Chimerix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-86.23 Mil. Therefore, Chimerix's EV-to-EBIT for today is 0.79.

The historical rank and industry rank for Chimerix's EV-to-EBIT or its related term are showing as below:

STU:CXF' s EV-to-EBIT Range Over the Past 10 Years
Min: -186.42   Med: -1.15   Max: 2.09
Current: 0.79

During the past 13 years, the highest EV-to-EBIT of Chimerix was 2.09. The lowest was -186.42. And the median was -1.15.

STU:CXF's EV-to-EBIT is ranked better than
71.36% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs STU:CXF: 0.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Chimerix's Enterprise Value for the quarter that ended in Mar. 2024 was €-63.51 Mil. Chimerix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was €-86.23 Mil. Chimerix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 135.77%.


Chimerix EV-to-EBIT Historical Data

The historical data trend for Chimerix's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chimerix EV-to-EBIT Chart

Chimerix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.23 -5.10 -5.38 0.85 1.03

Chimerix Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.69 1.68 1.12 1.03 0.68

Competitive Comparison of Chimerix's EV-to-EBIT

For the Biotechnology subindustry, Chimerix's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chimerix's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chimerix's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Chimerix's EV-to-EBIT falls into.



Chimerix EV-to-EBIT Calculation

Chimerix's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=-68.394/-86.234
=0.79

Chimerix's current Enterprise Value is €-68.39 Mil.
Chimerix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-86.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix  (STU:CXF) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Chimerix's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-86.234/-63.51304934
=135.77 %

Chimerix's Enterprise Value for the quarter that ended in Mar. 2024 was €-63.51 Mil.
Chimerix's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-86.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chimerix EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Chimerix's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Chimerix (STU:CXF) Business Description

Traded in Other Exchanges
Address
2505 Meridian Parkway, Suite 100, Durham, NC, USA, 27713
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through license agreements and a federal contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA) for research and advanced development of drugs to treat various human diseases. The company operates only in one business segment namely pharmaceuticals.

Chimerix (STU:CXF) Headlines

No Headlines